Wednesday, March 30, 2016 7:05:12 AM
Use of CytoSorb in a case of toxic shock syndrome
Dr. Erwin van der Linde, Dr. Albert Grootendorst
Department of Intensive Care Medicine, Maasstad Hospital, Rotterdam, the Netherlands
Summary:
This case study reports on a 17-year-old male who reported to the pediatrician at a local rural hospital with complaints of pretibial pain in his right leg, after he accidentally cut his leg while in the fields a few days earlier.
Case presentation
Diagnosis of a phlegmon with an abscess followed by surgical debridement with wound nettoyage with no clinical signs of subcutaneous emphysema or necrotising fasciitis
Postoperatively the patient’s condition deteriorated and after admission to ICU he developed erythema, spreading from the right lower leg to the right upper leg, abdominal wall and the left leg, consistent with toxic shock syndrome
Development of septic shock due to invasive S. aureus infection with respiratory failure, hemodynamic instability treated with vasopressors, hydrocortisone, antibiotic therapy
Due disease severity, CRRT was initiated with a CytoSorb adsorber with the only goal to remove cytokines (despite absence of acute kidney injury and no need/indication for renal replacement therapy)
Treatment
Cytosorb was used in conjunction with CRRT (Baxter HF 19 Aquamax)
One treatment was performed for 24 hours in total
Blood flow rate between 240 ml/min
Regional anti-coagulation was achieved using a citrate-based protocol
Measurements
Need for norepinephrine throughout the treatment period
CRP, hemoglobin, Hct, MCV (fl), thrombocytes, leucocytes, INR, aPTT, Urea, Crea, Phosphate, Bilirubin, Gamma GT, Alkaline phosphatase, ALAT, ASAT, LDH, Creatine kinase, Albumin, Lactate, pCO2, pO2 HCO3-, Base excess, Saturation, SvO2, PaO2:FiO2 ratio
Results
Within six hours after start of CytoSorb therapy, the erythema progression stopped and after 12 hours the need for vasopressors diminished
After 24 hours, vital signs were: sinus tachycardia (112 beats/min), blood pressure 117/49 mmHg without vasopressors, no more fever
The erythema diminished after a few hours and had disappeared after 24 hours
Patient Follow-Up
After cessation of CytoSorb diuretics were started because of fluid overload
Respiration improved, the ventilator support was diminished and the patient was extubated on day 5 after admission, within 72 hours of cessation of CRRT
On day 6, patient was transferred back to the local hospital for further revalidation
Conclusions
The progression of the erythema, together with that of the respiratory and circulatory failure, seemed to stop after six hours of CytoSorb therapy
The reduction in the erythema after the start of CytoSorb was remarkable and the need for vasopressors stabilized and decreased within six hours after initiation
In the authors opinion, the patient would have survived without CytoSorb, but they feel that his stay in the ICU might have been shortened by the CytoSorb adsorber
Randomized controlled trials will have to be performed to find out whether the theoretical beneficial effects of CytoSorb are clinically relevant, as well as the possibilities of unwanted side effects
Although the clinical value still has to be established, the first experiences with the CytoSorb adsorber are promising and justify further investigation
http://cytosorb-therapy.com/the-therapy/case-of-the-week/
Recent CTSO News
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:54 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM